Trial Updates Archives

First-line therapy in urothelial carcinoma: KEYNOTE-361 & DANUBE

Urothelial carcinoma updates presented at ESMO 2020: JAVELIN Bladder 100

The Lung Cancer Sessions

A three-part session with experts Solange Peters, Martin Reck, and Sanjay Popat, who discuss the latest updates in lung cancer…

ADAURA: osimertinib demonstrates significant clinical benefit in adjuvant NSCLC therapy

The first interim results of the Phase III ADAURA study evaluating adjuvant osimertinib in stage IB-IIIA EGFR-mutated non-small cell lung…

TP53 mutations predict sensitivity to adjuvant chemotherapy in pancreatic cancers

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive gastrointestinal malignancy and is often associated with a poor prognosis. Surgery remains…

FDA approve tucatinib for advanced unresectable or metastatic HER2-positive breast cancer

Seattle Genetics have announced the U.S. Food and Drug Administration (FDA) have granted approval for tucatinib in combination with trastuzumab…

FDA gives mitomycin gel green light for low-grade upper tract urothelial cancer

April 15th saw the Food and Drug Administration (FDA) approval of mitomycin gel (Jelmyto) for the treatment of low-grade upper…

Use of pembrolizumab in patients with PS2 NSCLC

Clinical trials assessing the efficacy of pembrolizumab have previously enrolled patients with performance status (PS) 0–1. However, almost a fifth…

CAR T-cell therapy guided by scorpion toxin for glioblastoma

The first chimeric antigen receptor T-cell (CAR T-cell) therapy using chlorotoxin (CLTX), a toxin found in the venom of scorpions,…

FDA accepts subcutaneous combination of pertuzumab and trastuzumab for HER2+ breast cancer

Breast cancer is the most common type of malignancy in women.1 Human epidermal growth factor receptor 2 (HER2) positive breast…

NHS approval for ovarian cancer drug, olaparib

Olaparib, a maintenance therapy for ovarian cancer, may prolong the benefit of initial treatment in BRCA1/2 mutated ovarian cancer patients…

World first in bladder cancer with FDA approval of erdafitinib

Following the release of trial data, the FDA has approved erdafitinib for the treatment of adult patients with fibroblast growth…

When radiation therapy causes heart disease

It has been known for almost a century that thoracic radiotherapy can cause damage to the heart.[2] However, the first…

features: Trial Updates